JP-2022531296-A5 -

Dates

Publication Date

20230511

Application Date

20200430

Description

[Invention 1001]A method for generating new neurons in a subject where such a need exists, comprising the step of administering TERT activation therapy to the subject.[Invention 1002]A method for treating neurodegenerative disorders in a subject, comprising the step of administering TERT activation therapy to the subject.[Invention 1003]The method of the present invention 1002, wherein the neurodegenerative disorder includes Alzheimer's disease.[Invention 1004]A method for reducing amyloid-beta peptide in a subject in need, comprising the step of administering TERT activation therapy to the subject.[Invention 1005]A method for treating premature aging disorders in a subject in need, comprising the step of administering TERT activation therapy to the subject.[Invention 1006]The method of the present invention 1005, wherein the premature aging disorder includes Hutchinson-Gilford progeria syndrome (HGPS), Nestor Guillermo progeria syndrome, Werner syndrome, Cockayne syndrome, Bloom syndrome, xeroderma pigmentosum, ataxia telangiectasia, trichorrhizosis, congenital keratosis, or anomalous mosaic syndrome.[Invention 1007]A method according to any of items 1001 to 1006 of the present invention, wherein the subject has been diagnosed with a disability.[Invention 1008]A method according to any of the present invention 1001 to 1007, wherein the subject has previously been treated for a defect.[Invention 1009]The method of the present invention 1008, wherein the subject has been determined to be unresponsive to previous therapies.[Invention 1010]A method according to any of the present invention 1001 to 1009, wherein the subject is a human.[Invention 1011]The method of the present invention 1010, wherein the subject is under 50 years of age.[Invention 1012]A method according to any one of the present invention 1001 to 1011, further comprising the administration of an additional therapy.[Invention 1013]A method according to any one of the present invention 1001 to 1012, wherein the TERT activation therapy comprises one or more nucleic acids encoding a TERT polypeptide.[Invention 1014]The method of the present invention 1013, wherein TERT activation therapy comprises DNA or RNA encoding a TERT polypeptide to a target.[Invention 1015]A method according to any one of the present invention 1001 to 1012, wherein the TERT activation therapy comprises a TERT polypeptide.[Invention 1016]A method according to any one of the present invention 1001 to 1015, wherein the TERT activation therapy comprises a nanovesicle containing a TERT polypeptide or a nucleic acid encoding a TERT polypeptide.[Invention 1017]The method of the present invention 1016, wherein the nanovesicle contains CD47.[Invention 1018]The method of the present invention 1016 or 1017, wherein the nanovesicle contains a rabies virus glycoprotein peptide.[Invention 1019]A method according to any one of items 1016 to 1018 of the present invention, wherein the nanovesicles are derived from fibroblasts or bone marrow dendritic cells.[Invention 1020]Any method according to invention 1016 to 1019, wherein the nanovesicles are derived from human cells.[Invention 1021]A method according to any one of the present invention 1001 to 1020, wherein TERT activation therapy includes the modification of histone H3K9 methyltransferase (HMT).[Invention 1022]The method of the present invention 1021, wherein the adjustment includes the suppression of an HMT gene or protein.[Invention 1023]The method of the present invention 1022, wherein the suppression includes gene silencing of one or more HMT genes.[Invention 1024]The method of the present invention 1023, wherein one or more HMT genes include one or more of SUV39H1/KMT1A, SUV39H2/KMT1B, SETDB1/KMT1E, SETDB2/KMT1F, PRDM2, G9A/KMT1C, GLP/KMT1D, EHMT1, and RIZ1/KMT8.[Invention 1025]The method of the present invention 1022, wherein TERT activation therapy includes an HMT inhibitor.[Invention 1026]The method of the present invention 1025, wherein the HMT inhibitor comprises one or more of ketosin, BIX-01294, BIX-01338, UNC0638, and BRD4770.[Invention 1027]A method according to any one of the present invention 1001 to 1020, wherein TERT activation therapy comprises the administration of a histone H3K9 demethylase (HDM) polypeptide or a nucleic acid encoding HDM.[Invention 1028]The method of the present invention 1027, wherein the HDM polypeptide comprises a polypeptide from one or more of KDM1A/LSD1, KDM3A/JHDM2A, KDM3B/JHDM2B, KDM4A/JHDM3A, KDM4B/JMJD2B, KDM4C/JMJD2C, KDM4D/JMJD2D, KDM7/JHDM1D, and PHF8.[Invention 1029]A method of the present invention described in any of items 1001 to 1028, wherein TERT activation therapy is administered by intravenous injection.[Invention 1030]A method of the present invention 1001 to 1029, wherein the treatment comprises one or more of the following: reduction of amyloid-beta peptide, improvement of learning, improvement of memory, and generation of neurons.[Invention 1031]A method according to any